



(11) **EP 1 722 229 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**25.11.2009 Bulletin 2009/48**

(45) Date of publication and mention  
of the grant of the patent:  
**07.10.2009 Bulletin 2009/41**

(21) Application number: **05701698.2**

(22) Date of filing: **03.02.2005**

(51) Int Cl.:  
**G01N 33/564** <sup>(2006.01)</sup> **G01N 33/566** <sup>(2006.01)</sup>  
**C07K 14/705** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/ES2005/000046**

(87) International publication number:  
**WO 2005/076000 (18.08.2005 Gazette 2005/33)**

(54) **METHOD OF ASSESSING RISK OF AND PREDISPOSITION TO THE DEVELOPMENT OF A PATHOLOGY RELATED TO THE PRESENCE OF ANTI-EPCR ANTIBODIES**

VERFAHREN ZUR BEURTEILUNG DER GEFAHR UND VERANLAGUNG, EINE MIT DEM VORLIEGEN VON ANTI-EPCR-ANTIKÖRPERN VERBUNDENE SYMPTOMATIK ZU ENTWICKELN

METHODE D'EVALUATION DU RISQUE ET DE LA PREDISPOSITION A DEVELOPPER UNE PATHOLOGIE ASSOCIEE A LA PRESENCE D'AUTOANTICORPS DU EPCR

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**  
Designated Extension States:  
**AL BA HR LV MK YU**

(30) Priority: **06.02.2004 ES 200400269**

(43) Date of publication of application:  
**15.11.2006 Bulletin 2006/46**

(73) Proprietor: **Proyecto de Biomedicina Cima, S.L.**  
**31180 Zizur Mayor - Navarra (ES)**

(72) Inventors:  
• **HERMIDA SANTOS, José**  
**31008 Pamplona (Navarra) (ES)**  
• **MONTES DIAZ, Ramon**  
**31008 Pamplona (Navarra) (ES)**  
• **HURTADO LINARES, Verónica**  
**31008 Pamplona (Navarra) (ES)**

(74) Representative: **ABG Patentes, S.L.**  
**Avenida de Burgos 16D**  
**Edificio Euromor**  
**28036 Madrid (ES)**

(56) References cited:  
**EP-A1- 0 600 088 US-A- 6 037 450**  
**US-B2- 6 617 145**

- **OOSTING J.D. ET AL: 'Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?.' BLOOD. vol. 81, no. 10, May 1993, pages 2618 - 2625, XP008070727**
- **GU J.M. ET AL: 'Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality.' THE JOURNAL OF BIOLOGICAL CHEMISTRY. vol. 277, no. 45, November 2002, pages 43335 - 43343, XP008042848**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 722 229 B8**